舌口腔咽喉頭領域の炎症に対するアズノール^®・ミニトローチの試用経験

抄録

Clinical study of Azulen^® “mini-troche” was carried out in 40 patients, with tongue, oral, pharyngeal and laryngeal inflammations in the mucosa of gingivobuccal sulcus, ten of which were lost to follow up.
The effects of Azulen^® “mini-troche” was as follows: for 30 cases excellent 5 (17%), good 10 (33%), poor 10 (33%), and none 5 (17%); for tongue and oral inflammation in 6 cases, excellent 1 (16%), good 0, poor 4 (67%), and none 1 (16%); for pharyngeal inflammation in 11 cases, excellent 1 (9%), good 4 (36%), poor 3 (27%), and none 3 (27%), including radiation injuries 1 excellent and another good; for laryngeal inflammation in 9 cases, excellent 2 (22%), good 4 (44%), poor 2 (22%), and none 1 (11%); for pharyngolaryngeal inflammation in 4 cases, excellent 1 (25%), good 2 (50%), poor 1 (25%), and none 0. For acute inflammation in 12 cases, excellent 3 (25%), good 7 (58%), poor 2 (16%), and none 0, for chronic inflammation in 18 cases, excellent 2 (11%), good 3 (16%), poor 8 (44%), and none 5 (27%). Subjective side effects were not complained of.
Azulen^® “mini-troche” appears safe and useful in upper respiratory inflammations, especially in pharyngeal and laryngeal inflammations, and radiation inflammations.